JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zorzet, S.
Right arrow Articles by Sava, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zorzet, S.
Right arrow Articles by Sava, G.

Vol. 295, Issue 3, 927-933, December 2000

Lack of In Vitro Cytotoxicity, Associated to Increased G2-M Cell Fraction and Inhibition of Matrigel Invasion, May Predict In Vivo-Selective Antimetastasis Activity of Ruthenium Complexes

Sonia Zorzet, Alberta Bergamo, Moreno Cocchietto, Alenka Sorc, Barbara Gava, Enzo Alessio, Elisabetta Iengo and Gianni Sava

Department of Biomedical Sciences (S.Z., G.S.), Callerio Foundation-Onlus, Trieste, Italy (A.B., M.C., A.S., B.G., G.S.); and Department of Chemical Sciences, University of Trieste, Trieste, Italy (E.A., E.I.)

The ruthenium complexes trans-dichlorotetrakisdimethylsulfoxide ruthenium(II) (trans-Ru), imidazolium trans-imidazoletetrachlororuthenate (ICR), sodium trans-tetramethylensulfoxideisoquinolinetetrachlororuthenate (TEQU), and imidazolium trans-imidazoledimethylsulfoxidetetrachlororuthenate (NAMI-A) are tested in vitro by short exposure of MCF-7, LoVo, KB, and TS/A tumor cells to 10-4 M concentration, and in vivo on Lewis lung carcinoma by a daily i.p. treatment for 6 consecutive days using equitoxic and maximum tolerated doses. NAMI-A 1) inhibited tumor cell invasion of matrigel, 2) induced a transient accumulation of cells in the G2-M phase, 3) did not modify in vitro cell growth, and 4) markedly reduced lung metastasis formation. TEQU showed significant cytotoxicity in vitro and was not antimetastatic in vivo. ICR and trans-Ru did not modify cell cycle distribution of in vitro tumor cells nor did they inhibit matrigel invasion; ICR was also devoid of antimetastasis effects in vivo. Ruthenium uptake by tumor cells did account for in vitro cytotoxicity but not for other in vitro actions or for in vivo antimetastasis activity. The contemporary absence of cytotoxicity, associated to inhibition of matrigel crossing and to transient block in the premitotic G2-M phase, appears to be prerequisites for a ruthenium compound to show in vivo-selective antimetastasis effect. The validation of this model for other classes of compounds will allow an understanding of the combined weight of the above-mentioned phenomena for tumor metastasis growth and control.


0022-3565/00/2953-0927$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
B. Gava, S. Zorzet, P. Spessotto, M. Cocchietto, and G. Sava
Inhibition of B16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell Invasion
J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 284 - 291.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. M. Rademaker-Lakhai, D. van den Bongard, D. Pluim, J. H. Beijnen, and J. H. M. Schellens
A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent
Clin. Cancer Res., June 1, 2004; 10(11): 3717 - 3727.
[Abstract] [Full Text] [PDF]


Home page
J Oncol Pharm PractHome page
M. Bouma, B. Nuijen, E. E Challa, G. Sava, A. Flaibani, A. Bult, and J. H Beijnen
Stability and compatibility of the investigational antimetastatic ruthenium complex NAMI-A in infusion systems and its hemolytic potential
Journal of Oncology Pharmacy Practice, March 1, 2004; 10(1): 7 - 15.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Bergamo, G. Stocco, B. Gava, M. Cocchietto, E. Alessio, B. Serli, E. Iengo, and G. Sava
Distinct Effects of Dinuclear Ruthenium(III) Complexes on Cell Proliferation and on Cell Cycle Regulation in Human and Murine Tumor Cell Lines
J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 725 - 732.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Sava, S. Zorzet, C. Turrin, F. Vita, M. Soranzo, G. Zabucchi, M. Cocchietto, A. Bergamo, S. DiGiovine, G. Pezzoni, et al.
Dual Action of NAMI-A in Inhibition of Solid Tumor Metastasis: Selective Targeting of Metastatic Cells and Binding to Collagen
Clin. Cancer Res., May 1, 2003; 9(5): 1898 - 1905.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.